New data on use of sebetralstat to treat HAE attacks in children (2-11 years old) presented at the 2026 Global Angioedema Leadership Conference
Data on the use of sebetralstat to treat HAE attacks in children aged between 2-11 years old was presented at the recent 2026 Global Angioedema Leadership Conference in Madrid.
The data looked at 172 HAE attacks in 33 children in the study, which is called KONFIDENT-KID. Each was treated with a tailored dose according to the child’s weight. Sebetralstat was given as an oral disintegrating tablet. The key findings were:
- Mean 0.7 attacks treated per patient per month
- Median time to treatment of 25 minutes, with 67% of attacks treated within the first hour; 88.9% were mild or moderate in severity
- Median times to symptom relief and complete resolution (150 mg dose group, largest cohort) were 1.5 hours and 12 hours, respectively
- Sebetralstat was well tolerated with no serious or treatment-related adverse events, and no reports of difficulty swallowing.
Dr Emel Aygören-Pürsün from University Hospital Frankfurt, said: “Managing HAE attacks in children remains particularly challenging, as currently available on-demand treatments rely on injections or intravenous infusions that can be painful, anxiety-inducing, and difficult to administer promptly at symptom onset. These barriers can contribute to treatment delays or avoidance, which may worsen outcomes.
“The KONFIDENT-KID data demonstrate that children and caregivers were able to treat attacks early and achieve rapid symptom relief with sebetralstat. This is especially meaningful in pediatric patients, where timely treatment can help limit swelling progression and reduce the overall duration and impact of an attack. An effective oral on-demand option has the potential to transform the treatment experience for children and families, reducing fear and burden while enabling early treatment of attacks.”
(Source: KalVista)